News & Press
Freespira raises $10M to eliminate panic attacks & PTSD symptoms.
Palo Alto Health Sciences, Inc. has a new name, Freespira, Inc.
Visit the site
Freespira, Inc. raised $10 million in new funding led by Lightspeed Venture Partners to further commercialize Freespira, the 28-day digital therapeutic treatment for panic attacks and PTSD.
View Press Release
The white paper, It’s Not “All in Your Head” A physiological approach to treating panic attacks and PTSD, was published.
Download White Paper
Providence Medical Technology Announces First Patient Enrollment in the “FUSE” IDE Clinical Study
The FUSE Study is designed to demonstrate the superiority of Circumferential Cervical Fusion over traditional ACDF in patients at high risk for nonunion or revisions.
PLEASANTON, Calif., June 15, 2020 /PRNewswire/ — Providence Medical Technology, Inc., a medical device innovator focused on improving surgical outcomes of the cervical spine, announced initiation of enrollment in a human clinical Investigational Device Exemption (IDE) study evaluating the safety and effectiveness of its Posterior Cervical Stabilization System (PCSS) in patients with 3-level degenerative disc disease. The first case was performed by Dr. Pierce Nunley, MD, Director of the Spine Institute of Louisiana in Shreveport, Louisiana.
Providence Medical Technology Secures $25 Million In Equity Financing
Proceeds to Bolster Commercial Expansion & Clinical Development of its DTRAX® Spinal System
Joint Purification Systems, Inc. Announces $7.8 Million Series A Financing
Joint Purification Systems Inc. announced today that it has closed a $7.8 million Series A financing.
SOLANA BEACH, CALIF. (PRWEB) APRIL 18, 2018
Joint Purification Systems Inc. (JPS), an early stage medical device company developing novel combination products to treat chronic peri-prosthetic joint infection (PJI), announced today that it has closed a $7.8 million Series A financing. The financing was led by Johnson & Johnson Innovation – JJDC, Inc. MedVest Fund II was also a new investor in the round. Proceeds will be used for preparation of the company’s first products in the X7 Spacer System for initiation of human clinical studies.
Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris Pharmaceuticals Co.
Capital will fuel continued research and clinical development of micro-infusion platform
EMERYVILLE, Calif., June 21, 2018 /PRNewswire/ — Mercator MedSystems, Inc., today announced it has received $11 million in Series D equity financing led by Shenzhen Salubris Pharmaceuticals Co. (Salubris), with participation from current Mercator investors and other undisclosed new investors. The new funding will further advance the clinical development of Mercator’s proprietary micro-infusion catheter systems and accelerate the company’s vision of improving outcomes in patients around the world with cardiovascular and pulmonary disease.
Mercator Medsystems leaps forward with Bullfrog into LIMBO-ATX trial
BioWorld MedTech, November 1, 2017